Clinical application effect of Pembrolizumab in the treatment of advanced cutaneous malignant melanoma

Lei Fu; Hui Zhang; Jingwen Jiang; Xuewu Chen; Lang Chen; Hui Gong

Clinical application effect of Pembrolizumab in the treatment of advanced cutaneous malignant melanoma

Am J Transl Res. 2021 May 15;13(5):5380-5385. eCollection 2021.

Authors

Lei Fu¹, Hui Zhang², Jingwen Jiang², Xuewu Chen², Lang Chen¹, Hui Gong³

Affiliations

¹ Department of Dermatology, Hainan Hospital of Traditional Chinese Medicine Haikou, Hainan Province, China.
² Department of Oncology, Hainan Hospital of Traditional Chinese Medicine Haikou, Hainan Province, China.
³ Department of Medical Oncology, Hu'nan Academy of Traditional Chinese Medicine Affiliated Hospital Changsha, Hu'nan Province, China.

PMID: 34150134
PMCID: PMC8205738

Abstract

Objective: To investigate the clinical application value of Pembrolizumab (PEM) in the treatment of advanced cutaneous malignant melanoma (ACMM).

Methods: The data of 56 patients with ACMM were retrospectively analyzed. According to the treatment methods, they were divided into a control group (30 cases) and an observation group (26 cases). Patients in the control group were given chemotherapy with Temozolomide (TEM), and patients in the observation group were treated with PEM on the basis of the treatment provided to the control group. The short-term therapeutic efficacy, long-term survival rate and the incidence of adverse reactions were compared between the two groups.

Results: After treatment, the short-term clinical effective rate was higher in the observation group than that in the control group (P<0.05). In addition, the survival time in the observation group was longer than that in the control group (P<0.001); and the one-year survival rate was higher in the observation group (53.85% vs. 40.00%, P>0.05). No statistical difference was found in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion: PEM can improve the short-term clinical effective recovery rate, long-term survival time and prognosis survival rate of patients with cutaneous malignant melanoma, with no increased incidence of drug-related adverse reactions. It is relatively safe and worthy of front-line clinical promotion and application.

Keywords: Advanced cutaneous malignant melanoma; Pembrolizumab; adverse reaction; chemotherapy; clinical efficacy.